



PATENT

Case Docket No. AIDAN.005A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Neil H. Riordan
Appl. No. : 10/647,131
Filed : August 22, 2003
For : METHOD AND
COMPOSITION FOR
PREVENTING OR REDUCING
EDEMA, DEEP VEIN
THROMBOSIS AND/OR
PULMONARY EMBOLISM
Examiner : Unknown
Group Art Unit : 1654

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

January 29, 2004
(Date)

Suzanne Jepson
Suzanne G. Jepson, Reg. No. 51,848

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 with thirty-five (35) references.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Suzanne Jepson
Suzanne G. Jepson
Registration No. 51,848
Agent of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Neil H. Riordan
App. No. : 10/647,131
Filed : August 22, 2003
For : METHOD AND COMPOSITION FOR
PREVENTING OR REDUCING EDEMA,
DEEP VEIN THROMBOSIS AND/OR
PULMONARY EMBOLISM
Examiner : Unknown
Group Art Unit : 1654

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:


Enclosed is form PTO-1449 listing thirty-five references. Copies of the references are enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,
KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: January 29, 2004

By: Suzanne Jepson
Suzanne G. Jepson
Registration No. 51,848
Agent of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	ATTY. DOCKET NO. AIDAN.005A	APPLICATION NO. 10/647131
	APPLICANT Neil H. Riordan	
	FILING DATE August 22, 2003	GROUP 1654

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
---------------------	-----------------	------	------	-------	----------	---------------------------------


FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	1	AMA Commission on Emergency Medical Services, <i>Medical Aspects of Transportation Aboard Commercial Aircraft</i> , JAMA, Vol. 247, No. 7, February 19, 1982, pp. 1007-1011
	2	Becker, Stefan R., <i>Pyknogenol: Eine Substanz mit kapillarprotektiver Wirkung</i> (2). Schweiz. Zschr. GanzheitsMedizin pp. 69-73, 1995.
	3	Belcaro, Abstracts of Original Contributions to Be Presented at the American College of Cardiology 51 st Annual Scientific Session, March 17-20, 2002, Atlanta, Georgia, 2 pages, Abstract #1032-77, March 6, 2002 (JACC)
	4	Belcaro, G., Supplement to Circulation, Abstracts from Scientific Sessions 2001, Anaheim Convention Center, Anaheim, California, November 11-14, 2001, Vol. 104, No. 17, October 23, 2001, 2 pages, (Abstract #2497, II-528)
	5	Belcaro, G., Supplement to Circulation, Abstracts from Scientific Sessions 2002, McCormick Place, Chicago, IL November 17-20, 2002, Vol. 106, No. 19, November 5, 2002 (Abstract #3556)
	6	Belcaro, et al., <i>Prevention of Edema, Flight Microangiopathy and Venous Thrombosis in Long Flights with Elastic Stockings. A Randomized Trial. The LONFLIT 4 Concorde Edema-SSL Study</i> , Angiology 53:635-645, 2002
	7	Belcaro, et al., <i>Venous Thromboembolism from Air Travel. The LONFLIT Study</i> . Angiology 52:369-374, 2001
	8	Bendz, et al., <i>Association between acute hypobaric hypoxia and activation of coagulation in human beings</i> , The Lancet, Vol. 356, pp. 1657-1658, November 11, 2000
	9	Bernard, Bendz, Collin and Reynolds, E-mail submission to correspondence@lancet.com, The Lancet, Vol. 358, September 8, 2001, pp. 837-839
	10	Cesarone, et al., <i>Flight Microangiopathy in Medium-to-Long Distance Flights: Prevention of Edema and Microcirculation Alterations with HR (Paroven, Venoruton; O-(β-hydroxyethyl)-rutosides): A Prospective, Randomized, Controlled Trial</i> , Cardiovasc Pharmacol Therapeut 7 (Supplement I):S17-S20, 2002
	11	Cesarone, et al., <i>Venous Thrombosis from Air Travel: The LONFLIT3 Study. Prevention with Aspirin vs Low-Molecular-Weight Heparin (LMWH) in High-Risk Subjects: A Randomized Trial.</i> , Angiology 53:1-6, 2002
	12	Chang, R., <i>A novel fibrinolysis serpinase-nattokinase</i> . NCBI - AF368283. 2001.
	13	Cruickshank, et al., <i>Air Travel and Thrombotic Episodes: The Economy Class Syndrome</i> , The Lancet, pp. 497-498, August 27, 1988
	14	Ferrari, et al., <i>Travel as a Risk Factor for Venous Thromboembolic Disease, A Case-Control Study</i> , Chest 115:440-444, February, 1999
	15	Fujita, et al., <i>Purification and Characterization of a strong Fibrinolytic enzyme (Nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan</i> , Biochemical and Biophysical Research Communications, 197: 1340-1347, 1993

EXAMINER	DATE CONSIDERED
----------	-----------------

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. AIDAN.005A	APPLICATION NO. 10/647131
 <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(USE SEVERAL SHEETS IF NECESSARY)</p>		APPLICANT Neil H. Riordan	
		FILING DATE August 22, 2003	GROUP 1654

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	16	Gabor, et al., <i>Die Kapillarwandresistenz und ihre Beeinflussung durch wasserlösliche Flavonderivate bei spontan hypertensischen Ratten</i> , Phleböl 22:178-182, 1993.
	17	Geroulakos, et al., <i>Economy-class Syndrome Presenting as Phlegmasia caerulea dolens</i> , Eur J Vasc Endovasc Surg 20:102-104, 2000
	18	Gertler, et al., <i>Ambient oxygen tension modulates endothelial fibrinolysis</i> , J. of Vascular Surgery, pp. 939-946, 1993.
	19	Homans, John, <i>Thrombosis of the deep leg veins due to prolonged sitting</i> , The New England Journal of Medicine, 250:4 148-149, 1954
	20	Hosoi, et al., <i>Characteristic of Deep Vein Thrombosis Associated with Prolonged Travel</i> , Eur J Vasc Endovasc Surg 24:235-238, 2002
	21	Incandela, et al., <i>Microangiopathy and Venous Ulceration: Topical Treatment with Essaven Gel. A Placebo-Controlled, Randomized Study</i> , Angiology 52:3 S17-S21, 2001
	22	Kraaijenhagen, et al., <i>Travel and risk of venous thrombosis</i> , The Lancet, 356:1492-1493, 2000
	23	Landgraf, et al., <i>Economy Class Syndrome: Rheology, Fluid Balance, and Lower Leg Edema During a Simulated 12-Hour Long Distance Flight</i> , Aviation, Space, and Environmental Medicine, pp. 930-935, 1994
	24	Mendis, et al., <i>Air travel and venous thromboembolism</i> , Bulletin of the World Health Organization 80 (5) pp 403-406, 2002
	25	Petrassi, C., <i>PYCNOGENOL® in chronic venous insufficiency</i> , Phytomedicine, Vol. 7(5), pp. 383-388, 2000
	26	Sarvesvaran, R., <i>Sudden Natural Deaths Associated with Commercial Air Travel</i> , Med. Sci. Law 26:2, 35-38, 1986
	27	Schmidtke, et al., <i>Pyknogenol: Das hydrostatische Ödem und seine medikamentöse Beeinflussung</i> , Schweiz. Zschr. GanzheitsMedizin pp. 114-115, 1995.
	28	Scurr, et al., <i>Frequency and prevention of symptomless deep-vein thrombosis in long-haul flights: a randomised trial</i> , The Lancet 357:1485-1489, 2001
	29	Sumi, et al., <i>Structure and fibrinolytic properties of Nattokinase</i> , Poster Presentations 1: Non-Mammalian PAs and Other Proteases, Fibrinolysis 6:86, 1992
	30	Sumi, et al., <i>Enhancement of the Fibrinolytic Activity in Plasma by Oral Administration of Nattokinase</i> , Acta Haematol 84:139-143, 1990
	31	Sumi, et al., <i>A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto: a typical and popular soybean food in the Japanese diet</i> , Experientia 43: pp. 1110-1112, 1987
	32	Sumi, et al., <i>Strong Prourokinase Activators proved in Japanese Soybean Cheese Natto</i> . Journal of the Japanese Society for Science and Technology, Nippon Shokuhin Kagaku Kogaku Kaishi 43:1124-1127, 1996
	33	Symington, et al., <i>Pulmonary Thromboembolism after Travel</i> , Br. J. Dis. Chest 71:138-140, 1977
	34	Teenan, et al., <i>Peripheral arterial thrombosis related to commercial airline flights: Another Manifestation of the Economy Class Syndrome</i> , BJCP, 46:165-166, 1992
	35	Urano, et al., <i>The Profibrinolytic Enzyme Subtilisin NAT Purified from Bacillus subtilis Cleaves and Inactivates Plasminogen Activator Inhibitor Type 1</i> , The Journal of Biological Chemistry, 276:27 pp. 24690-24696, 2001

S:\DOCS\SGJ\SGJ-3358.DOC:gem111103

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	